Skip to main content
SpringerLink
Log in

Juvenile Localized and Systemic Scleroderma

  • Chapter
  • First Online:
Scleroderma

  • 80 Accesses

Abstract

Juvenile localized scleroderma and juvenile systemic sclerosis (jSSc) are sclerotic disorders that differ greatly in their extent of involvement and prognosis. Juvenile localized scleroderma, also called morphea, involves the skin and subcutaneous tissues. It occurs in 4.7–20 per 100,000 children and is ten times more frequent than jSSc. Lesions range from very small plaques to extensive fibrotic lesions which may cause significant functional impairment and cosmetic deformity. Extracutaneous signs are most often seen in linear, generalized, and pansclerotic morphea. Disease onset is usually during childhood or adolescence, although onset in early infancy and even at birth has been described. For lesions that cross joints or cause functional or cosmetic impairment, methotrexate (MTX), initially in combination with corticosteroids, is the treatment of choice. Juvenile systemic sclerosis (jSSc) is a multisystem connective tissue disease, with an estimated incidence of 0.27 per million children. Approximately 5–10% of all adults with systemic sclerosis (SSc) report the onset of the disease during childhood. It has a variety of clinical manifestations, sometimes different from the adult form. Mixed connective tissue disease (MCTD) and overlap syndromes have features of jSSc and sometimes even fulfill the criteria of jSSc.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45(5):614–20.

    Article  CAS  PubMed  Google Scholar 

  2. Laxer R, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13.

    Article  PubMed  Google Scholar 

  3. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res. 2010;62(2):213–8.

    Article  Google Scholar 

  4. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96.

    Article  PubMed  Google Scholar 

  5. Wu E, Li S, Torok K, Virkud Y, Fuhlbrigge R, Rabinovich C, et al. A28: description of the juvenile localized scleroderma subgroup of the CARRA registry. Arthritis Rheumatol. 2014;66(S3):S43–4.

    Article  Google Scholar 

  6. Zulian F, Vallongo C, de Oliveira SKF, Punaro MG, Ros J, Mazur-Zielinska H, et al. Congenital localized scleroderma. J Pediatr. 2006;149(2):248–51.

    Article  PubMed  Google Scholar 

  7. Pequet MS, Holland KE, Zhao S, Drolet BA, Galbraith SS, Siegel DH, et al. Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients. Br J Dermatol. 2014;170(4):895–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Peterson LS, Nelson AM, Su WPD. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–76.

    Article  CAS  PubMed  Google Scholar 

  9. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Marzano A, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13(2):171–6.

    PubMed  Google Scholar 

  11. Jablonska S, Blaszczyk M. Long-lasting follow-up favours a close relationship between progressive facial hemiatrophy and scleroderma en coup de sabre*. J Eur Acad Dermatol Venereol. 2005;19(4):403–4.

    Article  CAS  PubMed  Google Scholar 

  12. Menni S, Marzano A, Passoni E. Neurologic abnormalities in two patients with facial hemiatrophy and sclerosis coexisting with morphea. Pediatr Dermatol. 1997;14(2):113–6.

    Article  CAS  PubMed  Google Scholar 

  13. Blaszczyk M, Jablonska S. Linear scleroderma en coup de sabre. Relationship with progressive facial hemiatrophy. Adv Exp Med Biol. 1999;455:101–4.

    Article  CAS  PubMed  Google Scholar 

  14. Sommer A, Gambichler T, Bacharach-Buhles M, von Rothenburg T, Altmeyer P, Kreuter A. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol. 2006;54(2):227–33.

    Article  PubMed  Google Scholar 

  15. Kakimoto C, Ross V, Uebelhoer N. En coup de sabre presenting as a port-wine stain previously treated with pulsed dye laser. Dermatol Surg. 2009;35(1):165–7.

    CAS  PubMed  Google Scholar 

  16. Kim HS, Lee JY, Kim HO, Park YM. En coup de sabre presenting as a port-wine stain initially treated with a pulsed dye laser. J Dermatol. 2011;38(2):209–10.

    Article  PubMed  Google Scholar 

  17. Petrov I, Gantcheva M, Miteva L, Vassileva S, Pramatarov K. Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood. Pediatr Dermatol. 2009;26(1):59–61.

    Article  PubMed  Google Scholar 

  18. Wollina U, Buslau M, Weyers W. Squamous cell carcinoma in pansclerotic morphea of childhood. Pediatr Dermatol. 2002;19(2):151–4.

    Article  PubMed  Google Scholar 

  19. Parodi PC, Riberti C, Draganic Stinco D, Patrone P, Stinco G. Squamous cell carcinoma arising in a patient with long-standing pansclerotic morphea. Br J Dermatol. 2001;144(2):417–9.

    Article  CAS  PubMed  Google Scholar 

  20. Maragh SH, Davis MDP, Bruce AJ, Nelson AM. Disabling pansclerotic morphea: clinical presentation in two adults. J Am Acad Dermatol. 2005;53(2, Supplement):S115–9.

    Article  PubMed  Google Scholar 

  21. Kura M, Jidai S. Disabling pansclerotic morphea of childhood with extracutaneous manifestations. Indian J Dermatol. 2013;58(2):159.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873–81.

    Article  PubMed  Google Scholar 

  23. Weber P, Ganser G, Frosch M, Roth J, Hulskamp G, Zimmer K. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol. 2000;27(11):2692–5.

    CAS  PubMed  Google Scholar 

  24. Guariso G, Conte S, Galeazzi F, Vettorato M, Martini G, Zulian F. Esophageal involvement in juvenile localized scleroderma: a pilot study. Clin Exp Rheumatol. 2007;25(5):786–9.

    CAS  PubMed  Google Scholar 

  25. Polcari I, Moon A, Mathes EF, Gilmore ES, Paller AS. Headaches as a presenting symptom of linear morphea en coup de sabre. Pediatrics. 2014;134(6):e1715–9.

    Article  PubMed  Google Scholar 

  26. Kraus V, Lawson EF, Scheven EV, Tihan T, Garza J, Nathan RG, et al. Atypical cases of scleroderma en coup de sabre. J Child Neurol. 2014;29(5):698–703.

    Article  PubMed  Google Scholar 

  27. Blaszczyk M, Królicki L, Krasu M, Glinska O, Jablonska S. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol. 2003;30(9):1997–2004.

    PubMed  Google Scholar 

  28. DeFelipe J, Segura T, Arellano JI, Merchán A, DeFelipe-Oroquieta J, Martín P, et al. Neuropathological findings in a patient with epilepsy and the Parry–Romberg syndrome. Epilepsia. 2001;42(9):1198–203.

    Article  CAS  PubMed  Google Scholar 

  29. Flores-Alvarado DE, Esquivel-Valerio JA, Garza-Elizondo M, Espinoza LR. Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship? J Rheumatol. 2003;30(1):193–5.

    PubMed  Google Scholar 

  30. Holland KE, Steffes B, Nocton JJ, Schwabe MJ, Jacobson RD, Drolet BA. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics. 2006;117(1):e132–6.

    Article  PubMed  Google Scholar 

  31. Zannin ME, Martini G, Athreya BH, Russo R, Higgins G, Vittadello F, et al. Ocular involvement in children with localised scleroderma: a multi-Centre study. Br J Ophthalmol. 2007;91(10):1311–4.

    Article  PubMed  PubMed Central  Google Scholar 

  32. El-Kehdy J, Abbas O, Rubeiz N. A review of parry-Romberg syndrome. J Am Acad Dermatol. 2012;67(4):769–84.

    Article  PubMed  Google Scholar 

  33. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology. 2005;44(3):274–9.

    Article  CAS  PubMed  Google Scholar 

  34. Warner Dharamsi J, Victor S, Aguwa N, et al. Morphea in adults and children cohort iii: nested case-control study—the clinical significance of autoantibodies in morphea. JAMA Dermatol. 2013;149(10):1159–65.

    Article  Google Scholar 

  35. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol. 2008;35(4):650–7.

    PubMed  Google Scholar 

  36. Arkachaisri T, Vilaiyuk S, Li S, O’Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36(12):2819–29.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kelsey C, Torok K. The localized scleroderma assessment tool: responsiveness to change in a pediatric clinical population. JAAD. 2013;69(2):214–20.

    Article  PubMed  Google Scholar 

  38. Zulian F, Meneghesso D, Grisan E, Vittadello F, Belloni Fortina A, Pigozzi B, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology. 2007;46(5):856–60.

    Article  CAS  PubMed  Google Scholar 

  39. Nezafati KA, Cayce RL, Susa JS, et al. 14-mhz ultrasonography as an outcome measure in morphea (localized scleroderma). Arch Dermatol. 2011;147(9):1112–5.

    Article  PubMed  Google Scholar 

  40. Porta F, Kaloudi O, Garzitto A, Prignano F, Nacci F, Falcini F, et al. High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma. Mod Rheumatol. 2014;24(5):869–73.

    Article  PubMed  Google Scholar 

  41. Li SC, Liebling MS, Haines KA, Weiss JE, Prann A. Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2011;63(5):735–42.

    Article  CAS  PubMed  Google Scholar 

  42. Li SC, Liebling MS, Haines KA. Ultrasonography is a sensitive tool for monitoring localized scleroderma. Rheumatology. 2007;46(8):1316–9.

    Article  CAS  PubMed  Google Scholar 

  43. Martini G, Murray KJ, Howell KJ, Harper J, Atherton D, Woo P, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology. 2002;41(10):1178–82.

    Article  CAS  PubMed  Google Scholar 

  44. Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Care Res. 2006;55(4):603–9.

    Article  Google Scholar 

  45. Kuwahara Y, Shima Y, Kawai M, Hagihara K, Hirano T, Arimitsu J, et al. What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al. Arthritis Care Res. 2008;59(4):601.

    Article  Google Scholar 

  46. Liu P, Uziel Y, Chuang S, Silverman E, Krakfchik B, Laxer R. Localized scleroderma: imaging features. Pediatr Radiol. 1994;24(3):207–9.

    Article  CAS  PubMed  Google Scholar 

  47. Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol–betamethasone dipropionate for morphoea. Br J Dermatol. 2007;157(3):615–8.

    Article  CAS  PubMed  Google Scholar 

  48. Cunningham BB, Landells IDR, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2):211–5.

    Article  CAS  PubMed  Google Scholar 

  49. Kroft E, Groeneveld T, Seyger M, Jong ED. Efficacy of topical tacrolimus 0.1% in active plaque morphea. Am J Clin Dermatol. 2009;10(3):181–7.

    Article  PubMed  Google Scholar 

  50. Cantisani C, Miraglia E, Richetta A, Mattozzi C, Calvieri S. Generalized morphea successfully treated with tacrolimus 0.1% ointment. J Drugs Dermatol. 2013;12(1):14–5.

    PubMed  Google Scholar 

  51. Pope E, Doria AS, Theriault M, Mohanta A, Laxer RM. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline open-label pilot study. Dermatology. 2011;223(4):363–9.

    Article  CAS  PubMed  Google Scholar 

  52. Rodriquez-Castellanos M, Tlacuilo-Parra A, Sanchez-Enriquez S, Velez-Gomez E, Guevara-Gutierrez E. Pirfenidone gel in patients with localized scleroderma: a phase II study. Arthritis Res Ther. 2014;16(6):510.

    Article  Google Scholar 

  53. Vasquez R, Jabbar A, Khan F, Buethe D, Ahn C, Jacobe H. Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study. J Am Acad Dermatol. 2014;70(3):481–8.

    Article  PubMed  Google Scholar 

  54. Caca-Biljanovska N, Vickova-Laskoska M, Dervendi D, Pesic N, Laskoski D. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol. 1999;455:299–304.

    Article  CAS  PubMed  Google Scholar 

  55. Hulshof M, Bavinck JB, Bergman W, Masclee A, Heickendorff L, Breedveld F, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000;43(6):1017–23.

    Article  CAS  PubMed  Google Scholar 

  56. Koch SB, Cerci FB, Jorizzo JL, Krowchuk DP. Linear morphea: a case series with long-term follow-up of young, methotrexate-treated patients. J Dermatol Treat. 2013;24(6):435–8.

    Article  CAS  Google Scholar 

  57. Seyger MMB, van den Hoogen FHJ, de Boo T, de Jong EMGJ. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol. 1998;39(2):220–5.

    Article  CAS  PubMed  Google Scholar 

  58. Uziel Y, Feldman BM, Krafchik BR, Yeung RSM, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136(1):91–5.

    Article  CAS  PubMed  Google Scholar 

  59. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol. 2005;141(7):847–52.

    Article  CAS  PubMed  Google Scholar 

  60. Fitch PG, Rettig P, Burnham JM, Finkel TH, Yan AC, Akin E, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol. 2006;33(3):609–14.

    CAS  PubMed  Google Scholar 

  61. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006;155(5):1013–20.

    Article  CAS  PubMed  Google Scholar 

  62. Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006.

    Article  CAS  PubMed  Google Scholar 

  63. Zulian F, Vallongo C, Patrizi A, Belloni-Fortina A, Cutrone M, Alessio M, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–6.

    Article  CAS  PubMed  Google Scholar 

  64. Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res. 2012;64(8):1175–85.

    Article  CAS  Google Scholar 

  65. Amarilyo G, Rullo OJ, McCurdy DK, Woo JM, Furst DE. Folate usage in MTX-treated juvenile idiopathic arthritis (JIA) patients is inconsistent and highly variable. Rheumatol Int. 2013;33(9):2437–40.

    Article  PubMed  Google Scholar 

  66. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology. 2009;48(11):1410–3.

    Article  PubMed  Google Scholar 

  67. Inamo Y, Ochiai T. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate. Pediatr Dermatol. 2013;30(6):e191–3.

    Article  PubMed  Google Scholar 

  68. Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167(5):1138–44.

    Article  CAS  PubMed  Google Scholar 

  69. Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72(7):1217–20.

    Article  CAS  PubMed  Google Scholar 

  71. Stausbol-Gron B, Olesen AB, Deleuran B, Deleuran MS. Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases. Acta Derm Venereol. 2011;91(6):686–8.

    Article  PubMed  Google Scholar 

  72. Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7.

    Article  CAS  PubMed  Google Scholar 

  73. Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European scleroderma trial and research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–94.

    Article  CAS  PubMed  Google Scholar 

  74. Wollina U, Looks A, Schneider R, Maak B. Disabling morphoea of childhood—beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol. 1998;23(6):292–3.

    Article  CAS  PubMed  Google Scholar 

  75. Lapiere J-C, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup de sabre by en bloc autologous dermal fat graft. Dermatol Surg. 2000;26(8):793–7. https://doi.org/10.1046/j.524-4725.2000.00073.x.

    Article  CAS  PubMed  Google Scholar 

  76. Palmero MLH, Uziel Y, Laxer RM, Forrest CR, Pope E. En coup de sabre scleroderma and parry-Romberg syndrome in adolescents: surgical options and patient-related outcomes. J Rheumatol. 2010;37(10):2174–9.

    Article  PubMed  Google Scholar 

  77. Zhao J, Chenggang Y, Binglun L, Yan H, Li Y, Xianjie M, et al. Autologous fat graft and bone marrow-derived mesenchymal stem cells assisted fat graft for treatment of parry-Romberg syndrome. Ann Plast Surg. 2014;73(Suppl 1):S99–103.

    CAS  Google Scholar 

  78. Baildam EM, Ennis H, Foster HE, Shaw L, Chieng AS, Kelly J, et al. Influence of childhood scleroderma on physical function and quality of life. J Rheumatol. 2011;38(1):167–73.

    Article  PubMed  Google Scholar 

  79. Das S, Bernstein I, Jacobe H. Correlates of self-reported quality of life in adults and children with morphea. J Am Acad Dermatol. 2014;70(5):904–10.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Piram M, McCuaig CC, Saint-Cyr C, Marcoux D, Hatami A, Haddad E, et al. Short- and long-term outcome of linear morphoea in children. Br J Dermatol. 2013;169(6):1265–71.

    Article  CAS  PubMed  Google Scholar 

  81. Mertens JS, Seyger MMB, Kievit W, Hoppenreijs EPAH, Jansen TLTA, van de Kerkhof PCM, et al. Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with pediatric or adult-onset disease. Br J Dermatol. 2015;172(3):722–8.

    Article  CAS  PubMed  Google Scholar 

  82. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213–8.

    Article  PubMed  Google Scholar 

  83. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, et al. The pediatric rheumatology European society/American College of Rheumatology/European league against rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203–12.

    Article  PubMed  Google Scholar 

  84. Tyndall A, Furst D. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol. 2007;19(6):604–10.

    Article  PubMed  Google Scholar 

  85. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953–62.

    Article  CAS  PubMed  Google Scholar 

  86. Reiff A, Weinberg KI, Triche T, Masinsin B, Mahadeo KM, Lin CH, et al. T lymphocyte abnormalities in juvenile systemic sclerosis patients. Clin Immunol. 2013;149(1):146–55.

    Article  CAS  PubMed  Google Scholar 

  87. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:iii3–7.

    CAS  PubMed  Google Scholar 

  88. Halper J, Kjaer M. Basic components of connective tissues and extracellular matrix: elastin, fibrillin, fibulins, fibrinogen, fibronectin, laminin, tenascins and thrombospondins. Adv Exp Med Biol. 2014;802:31–47.

    Article  CAS  PubMed  Google Scholar 

  89. Castelino FV, Varga J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Curr Opin Rheumatol. 2014;26(6):607–14.

    Article  CAS  PubMed  Google Scholar 

  90. Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S75–86.

    PubMed  Google Scholar 

  91. Mayes MD, Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther. 2007;9(Suppl 2):S2–5.

    Article  Google Scholar 

  92. Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Dermatol. 2011;29(2 Suppl 65):S75–86.

    Google Scholar 

  93. Mayes M, Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther. 2007;9(Suppl 2):S5.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Foeldvari I, Zhavania M, Birdi N, Cuttica RJ, de Oliveira SH, Dent PB, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford). 2000;39(5):556–9.

    Article  CAS  PubMed  Google Scholar 

  95. Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971–8.

    Article  CAS  PubMed  Google Scholar 

  96. Aoyama K, Nagai Y, Endo Y, Ishikawa O. Juvenile systemic sclerosis: report of three cases and review of Japanese published work. J Dermatol. 2007;34(9):658–61.

    Article  PubMed  Google Scholar 

  97. Russo R, Katsicas M. Clinical characteristics of children with juvenile systemic sclerosis: follow-up of 23 patients in a single tertiary center. Pediatr Rheumatol Online J. 2007;5:6.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Misra R, Singh G, Aggarwal P, Aggarwal A. Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia. Clin Rheumatol. 2007;26(8):1259–62.

    Article  PubMed  Google Scholar 

  99. Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21(11):2143–6.

    CAS  PubMed  Google Scholar 

  100. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.

    Article  PubMed  Google Scholar 

  101. Terreri MT, Andrade LE, Puccinelli ML, Hilario MO, Goldenberg J. Nail fold capillaroscopy: normal findings in children and adolescents. Semin Arthritis Rheum. 1999;29(1):36–42.

    Article  CAS  PubMed  Google Scholar 

  102. Ingegnoli F, Herrick AL. Nailfold capillaroscopy in pediatrics. Arthritis Care Res (Hoboken). 2013;65(9):1393–400.

    Article  PubMed  Google Scholar 

  103. Herrick ML, Moore T, Hollis S, Jayson MIV. The influence of age on nailfold capillary dimension in childhood. J Rheumatol. 2000;27:797–800.

    CAS  PubMed  Google Scholar 

  104. Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis. 2003;62:444–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum. 2010;62(9):2595–604.

    Article  PubMed  Google Scholar 

  106. Foeldvari I, Wierk A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology. 2006;45:76–8.

    Article  CAS  PubMed  Google Scholar 

  107. Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176(2):174–80.

    Article  PubMed  Google Scholar 

  108. Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: normal values for children of 4–11 years of age. Arch Dis Child. 2008;93(6):464–8.

    Article  CAS  PubMed  Google Scholar 

  109. Panigada S, Ravelli A, Silvestri M, Granata C, Magni-Manzoni S, Cerveri I, et al. HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr Pulmonol. 2009;44(12):1226–34.

    Article  PubMed  Google Scholar 

  110. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004–13.

    PubMed  Google Scholar 

  111. Lanteri A, Sobanski V, Langlois C, Lefevre G, Hauspie C, Sanges S, et al. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev. 2014;13(9):974–80.

    Article  CAS  PubMed  Google Scholar 

  112. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370(5):433–43.

    Article  PubMed  Google Scholar 

  113. Castelino FV, Varga J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol. 2013;9(11):1077–90.

    Article  CAS  PubMed  Google Scholar 

  114. Kolto G, Vuolteenaho O, Szokodi I, Faludi R, Tornyos A, Ruskoaho H, et al. Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study. Clin Exp Rheumatol. 2014;32(Suppl 86 (6)):75–81.

    Google Scholar 

  115. Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, et al. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis. 2014;73(2):420–7.

    Article  PubMed  Google Scholar 

  116. Vesely R, Vargova V, Ravelli A, et al. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic scleroderma. J Rheumatol. 2004;31:795–800.

    PubMed  Google Scholar 

  117. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol. 2009;135(1):21–6.

    Article  PubMed  Google Scholar 

  118. Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res. 2008;63(3):321–7.

    Article  PubMed  Google Scholar 

  119. Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 2009;135(3):745–51.

    Article  CAS  PubMed  Google Scholar 

  120. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8.

    Article  CAS  PubMed  Google Scholar 

  121. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490–8.

    Article  PubMed  Google Scholar 

  122. Lehman T. Methotrexate for the treatment of early diffuse scleroderma: comment on the article by Pope et al. Arthritis Rheum. 2002;46(3):845.

    Article  PubMed  Google Scholar 

  123. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007;66(12):1641–7.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int. 2012;32(8):2431–44.

    Article  CAS  PubMed  Google Scholar 

  126. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193–7.

    Article  CAS  PubMed  Google Scholar 

  127. Daoussis D, Liossis S, Tsamandas A, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Dermatol. 2012;30(2 Suppl 71):S17–22.

    Google Scholar 

  128. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S17–22.

    PubMed  Google Scholar 

  129. Distler J, Jordan S, Airo P, Alegre-Sancho J, Allanore Y, Gurman AB, et al. Is there a role for TNFalpha antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S40–5.

    PubMed  Google Scholar 

  130. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68(9):1433–9.

    Article  CAS  PubMed  Google Scholar 

  131. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Foeldvari I, Nihtyanova SI, Wierk A, Denton CP. Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort. J Rheumatol. 2010;37:2422–6.

    Article  PubMed  Google Scholar 

  133. Foeldvari I, Tyndall A, Zulian F, Muller-Ladner U, Czirjak L, Denton C, et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford). 2012;51:1832–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Northwestern University, McGraw Medical Center, Chicago, IL, USA

    Lauren V. Graham

  2. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Amy S. Paller

  3. Hamburg Centre for Pediatric Rheumatology, Head of the Juvenile Scleroderma Working Group (JSScWG), Hamburger Zentrum Für Kinder- und Jugendrheumatologie, Hamburg, Germany

    Ivan Foeldvari

Authors
  1. Lauren V. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy S. Paller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan Foeldvari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivan Foeldvari .

Editor information

Editors and Affiliations

  1. INSERMU1016, Université Paris Cité,, Service de Rhumatologie, Hôpital Cochin,, Paris, France

    Yannick Allanore

  2. Department of Internal Medicine, University of Michigan–Ann Arbor, Ann Arbor, MI, USA

    John Varga

  3. Centre for Rheumatology, University College London, Royal Free Campus, London, UK

    Christopher P. Denton

  4. Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Tokyo, Japan

    Masataka Kuwana

  5. Rheumatology, Stanford Medicine, Redwood City, CA, USA

    Lorinda Chung

  6. Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Ami A. Shah

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Graham, L.V., Paller, A.S., Foeldvari, I. (2024). Juvenile Localized and Systemic Scleroderma. In: Allanore, Y., Varga, J., Denton, C.P., Kuwana, M., Chung, L., Shah, A.A. (eds) Scleroderma. Springer, Cham. https://doi.org/10.1007/978-3-031-40658-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-40658-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-40657-7

  • Online ISBN: 978-3-031-40658-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation